ArticleCancer discovery2020
An
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 126 citations in OpenAlex.
- Chromatin Modifications Orchestrate DNA Repair Pathway Choice: Epigenetics Strategies for Enhancing CRISPR-Cas9-Mediated Knock-In Efficiency.Cell proliferation · 2026Review
- Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance.Nature genetics · 2026Article
- Baseline cellular state shapes the molecular impact of mutant Kirsten rat sarcoma viral oncogene homologue (KRAS) alleles in reconstituted pancreatic cancer cells.Molecular omics · 2026Article
- Endothelial cell-intrinsic NOD2 signaling regulates the intestinal immune response through the generation of effector and memory T cells.Nature immunology · 2026Article
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis.Developmental cell · 2026Article
- CDK8 remodels the tumor microenvironment and promotes resistance to KRASThe EMBO journal · 2026Article
- Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nature communications · 2026Article
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Cancer cell · 2026Article
- Dynamic transitioning between MAPK-driven and WNT-driven cell states drives intestinal cancer and shapes therapy response.Nature genetics · 2026Article
- The impact of K-Ras Gly12 mutants on homeostasis and tumorigenesis in the colonic epithelium.Oncogene · 2026Article
- A catalogue of missense and nonsense mutation abundances for the U.S. cancer patient population.medRxiv : the preprint server for health sciences · 2026Article
- PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer.Cancer research · 2026Article
- Dual RAF inhibition outperforms RAF-MEK combinations for suppressing ERK signaling in KRAS mutant cells.NPJ systems biology and applications · 2026Article
- Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.Cancer research · 2026Article
- KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.Cancer research · 2026Article
- Oncogenic Alterations in PI3K Signaling Emulated Optogenetically Recapitulate Some Phenotypic Changes in Mammary Epithelia.ACS synthetic biology · 2026Article
- Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Science translational medicine · 2026Article
- Prognostic Implications of Codon-SpecificJCO precision oncology · 2026Article
- MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.Nature · 2026Article
- Characterization of a bronchoscopically induced transgenic lung cancer pig model for human translatability.Lab animal · 2026Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 1 country.
Maria Paz ZafraSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York. lud2005@med.cornell.edu mpz2001@med.cornell.edu.
Marie J ParsonsSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID https://orcid.org/0000-0002-4046-2491
Jangkyung KimWeill Cornell Graduate School of Medical Sciences, Weill Cornell Medicine, New York, New York.
Direna Alonso-CurbeloCancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sukanya GoswamiSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Emma M SchatoffSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID https://orcid.org/0000-0002-7327-1843
Teng HanSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Alyna KattiSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.
Maria Teresa Calvo FernandezSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID https://orcid.org/0000-0003-2583-2199
John E WilkinsonDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Elena PiskounovaSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.ORCID https://orcid.org/0000-0002-8554-8475
Lukas E DowSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York. lud2005@med.cornell.edu mpz2001@med.cornell.edu.ORCID https://orcid.org/0000-0001-7048-1418
Cornell University · USMemorial Sloan Kettering Cancer Center · USUniversity of Washington · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MA scalable platform for target validation in GEMM models of gastrointestinal malignancies.R01CA195787 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W. · 2015 to 2017
$2.0MMolecular and Translational Oncology ResearchT32CA203702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLENIS, JOHN, GIANNAKAKOU, PARASKEVI · 2017 to 2021
$1.4MSensitizing Colorectal Cancer to Checkpoint Inhibitors by WNT Pathway SuppressionF31CA247351 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATTI, ALYNA · 2020 to 2022
$127kNCI NIH HHS F31 CA247351NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA195787NCI NIH HHS T32 CA203702
Abstract
PubMed holds no abstract for this paper.
Indexed as
AllelesCell Line, TumorHumansOncogenesPhenotypeProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.